Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
Trial details
- Registry ID
- NCT02244606
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive CandidiasisNCT02244606 | SCYX | Phase 2 | Completed | 2016-06Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |